生产企业：Longboard Pharmaceuticals, Lundbeck
Bexicaserin (LP352) is an investigational therapy undergoing Phase III clinical evaluation for seizures associated with developmental and epileptic encephalopathies (DEEs). In December 2025, Lundbeck presented positive Phase II long-term data for bexicaserin in rare childhood-onset epilepsies at the American Epilepsy Society (AES) Annual Meeting. It is the only 5-HT2C receptor superagonist being dose-optimized specifically for refractory epilepsy.
Bexicaserin (LP352) is an investigational therapy undergoing Phase III clinical evaluation for seizures associated with developmental and epileptic encephalopathies (DEEs). In December 2025, Lundbeck presented positive Phase II long-term data for bexicaserin in rare childhood-onset epilepsies at the American Epilepsy Society (AES) Annual Meeting. It is the only 5-HT2C receptor superagonist being dose-optimized specifically for refractory epilepsy.
Bexicaserin is an orally administered, centrally acting 5-HT2C superagonist. It regulates GABA signaling, thereby reducing the neuronal hyperexcitability responsible for seizures. It is currently the only 5-HT2C receptor superagonist being dose-optimized specifically for patients with refractory epilepsy.
Seizures in children and adults living with developmental and epileptic encephalopathies (DEEs)
共 5 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
